Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L04AA56
|
| gptkbp:brand |
Enjaymo
|
| gptkbp:CASNumber |
1610353-18-0
|
| gptkbp:developer |
gptkb:Sanofi
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sutimlimab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
complement inhibitor
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
C1s protein
|
| gptkbp:UNII |
2ZB4F6E1Y8
|
| gptkbp:usedFor |
cold agglutinin disease
|
| gptkbp:bfsParent |
gptkb:Servier_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|